Detection of secreted signaling molecules by cognate cell surface receptors is a major intercellular communication pathway in cellular circuits that control biological processes. Understanding the biological significance of these connections would allow us to understand how cellular circuits operate as a whole.
Physiology and behavior of multicellular organisms are controlled by cellular circuits that detect prevailing external sensory cues and internal states and process the information into physiological and behavioral consequences. The individual cells of these circuits communicate with each other by secretion of neurotransmitters, neuropeptides, and hormones, which activate cell-surface receptors that specifically detect the secreted signals. The identification of the cellular constituents of circuits and functional characterization of connectivity within a circuit are key biological questions. However, diffusible bioactive agents for the study of cellular circuits in vivo have the limitation that their activity cannot be spatially controlled with cellular resolution.
The characterization of Lynx1, a membranebound peptide modulator of the nicotinic acetylcholine receptor (nAChR), has led to the design principle for membrane-tethered chimeric fusion proteins that cell-autonomously modulate target ion channels and receptors with pharmacological specificity while not influencing those same targets expressed in neighboring cells by presenting bioactive neurotoxins and neuropeptides to the extracellular surface. In this review, we discuss the development of pharmacologically specific cell-autonomous membrane-tethered peptide ligands and their application to dissecting and influencing biological circuits in vivo.
Development of Lynx1-Based CellAutonomous and Pharmacologically Specific T-Toxins
Lynx1, an endogenous nAChR inhibitor found in vertebrates and insects, is a GPI-tethered prototoxin, where the bioactive Lynx1 peptide is displayed on the extracellular face of the plasma membrane via covalent linkage to a GPI glycolipid molecular anchor (7, 20, 22, 25, 38) . The extracellular presentation of the Lynx1 peptide is determined by two sequence motifs that flank the Lynx1 nAChR-binding domain: an NH 2 -terminal secretory signal sequence that targets Lynx1 to the secretory pathway and a COOH-terminal GPI-targeting sequence that is detected by the ER enzyme GPI transamidase (GPIT) that cleaves the polypeptide upstream of the GPI targeting sequence and covalently links the liberated COOH terminus to the sugar chain of a GPI molecule (29) .
This modular structure of Lynx1 was adapted in the design of recombinant plasmid constructs for membrane-tethered expression of exogenous peptide neurotoxins from cone snail or snake venoms with unique specificities for different voltage-gated ion channel or nAChR subtypes (t-toxins) (21) . These t-toxins exhibit two key functional properties: 1) they maintain the pharmacological specificity of the encoded neurotoxin, and 2) their bioactivity is cell autonomous (i.e., limited to the cell that expresses the t-toxin). When t-toxins encoding nAChR-specific neurotoxins were each co-expressed with different nAChR subtypes in Xenopus oocytes, they inhibited nAChR subtypes specific to the neurotoxin and not other nAChR subtypes (21) . Similarly, t-toxins encoding voltagegated sodium channel-or voltage-gated calcium channel-specific neurotoxins maintained the specificities of their respective neurotoxins, demonstrating that membrane tethering of neurotoxins preserves their pharmacological specificity (21) . Also, in mixed cultures of oocytes expressing nAChR and oocytes co-expressing nAChR and its specific t-toxin, ACh-induced currents were blocked only in the oocyte population that expresses the t-toxin, indicating that the t-toxin acts on its targets in a cell-autonomous manner (21) .
Design Principles of MembraneTethered Peptide Ligands
Based on the Lynx1-like t-toxins, a variety of membrane-tethered ligand transgenes have been generated with useful variations on the original design. Studies with these tethered ligands reveal that the molecular design can be modified while maintaining pharmacological specificity and cell autonomy, as long as the basic modular design elements are included: 1) a bioactive ligand peptide sequence, 2) a hydrophobic anchor embedded in the plasma membrane, and 3) a flexible hydrophilic linker connecting the peptide to the anchor (FIGURE 1).
Bioactive Peptide and Pharmacological Specificity
The neurotoxin sequence presented on the extracellular surface determines the pharmacology of t-toxins. For example, O-conotoxin MrVIA selectively blocks tetrodotoxin (TTX)-resistant voltagegated sodium channels vs. TTX-sensitive channels in dorsal root ganglion (DRG) primary cultures, and DRG cultures expressing membrane-tethered MrVIA (t-MrVIA) exhibit ϳ40% reduced TTX-resistant voltage-gated currents, which corresponds to the efficacy of 100 nM soluble MrVIA (8, 34) . Similarly, ␦-ACTX-Hv1a inhibits sodium channel inactivation in cockroach and rat neuronal cultures, and membrane-tethered ␦-ACTX-Hv1a (t-␦-ACTX) inhibits Drosophila para voltage-gated sodium channel inactivation when co-expressed in Xenopus oocytes (12, 37) . Numerous other t-toxins have been used to cell-autonomously modulate ion channels and ionotropic receptors in a predictable way determined by the pharmacology of the tethered neurotoxin (1, 18, 21, 37) .
This membrane-tethering approach has been applied to endogenous neuropeptides as well to generate chimeric membrane-tethered peptides (t-peptides) analogous to the t-toxins described above. In cultured HEK293 cells, membranetethered forms of the Drosophila neuropeptides pigment-dispersing factor (PDF, t-PDF) and diuretic hormone 31 (DH31, t-DH31) each activated their cognate Class B1 GPCRs, PDF receptor (PDFR), and DH31 receptor (DH31R) without inducing
FIGURE 1. Modular architecture of membrane-tethered ligands
Schematics showing the various GPI-and TM-anchored membrane-tethered ligand architectures as expressed in the plasma membrane and the previous studies describing membrane-tethered ligands using each design. Each design contains the basic modular design elements: a bioactive ligand peptide (green), a hydrophobic anchor (orange), and a flexible hydrophilic linker connecting the peptide to the anchor (blue).
significant long-term desensitization common for GPCRs continuously exposed to agonists (6) . However, t-PDF did not activate any of the close Drosophila homologs of PDFR, DH31R, or diuretic hormone 44 receptor (DH44R), indicating its ability to discriminate between the most similar targets (6, 15) . Similarly, t-DH31 activated its cognate DH31R, but neither DH44 nor PDFR, which is activated by soluble DH31 with a lower efficacy and EC 50 than PDF, demonstrated that membranetethering preserves and possibly improves the pharmacological specificity of neuropeptides (6, 24) . Following these initial experiments demonstrating the feasibility of the t-toxin approach, the specific bioactivity of tethered forms of mammalian hormones and the yeast mating pheromone ␣-factor to their cognate receptors have also been demonstrated (11, 14) . Taken together, these studies establish the membrane-tethering approach as a generally viable method for activating plasma membrane receptors of endogenously secreted signaling peptides.
The specific bioactivities of neurotoxins and endogenous signaling peptides are preserved in their membrane-tethered forms by the minimal disruption of the bioactive conformation of the ligand. Neurotoxins used in the bioactive t-toxins have characteristic multiple disulfide bridges or cysteine loops with variable sequences in between that are likely to be responsible for their diverse molecular targets (8) . Thus the addition of a covalent bond at the toxin COOH terminus for tethering is unlikely to disrupt the structure of the target-binding surface, preserving the specific bioactivity of the toxin. Similarly, the receptor activation domain of Class B1 GPCR ligands and yeast ␣-factor lie in their NH 2 terminus, which is minimally influenced by the covalent link to the anchor placed at the ligand COOH terminus (17, 26) . The COOH terminus of Class B1 GPCR ligands determines the ligand affinity to their cognate receptors, and its disruption in t-DH31 is likely to be responsible for its more specific pharmacological profile (6, 17, 24) . If the functional binding motifs of neurotoxins or receptor activations of peptides are disrupted in the tethered from, the bioactivity of t-toxins or t-peptides is compromised. Highly posttranslationally modified toxins sometimes fail to exhibit bioactivity when tethered (18, 21) , and Class A GPCR ligands with COOH-terminal receptor activation domains, such as NPF and SIF, are completely inactive with COOH-terminal tethers (data not shown), indicating a limitation of the COOH-terminal tethering design.
Membrane Anchor and Cell Autonomy
The cell autonomy of t-toxins and t-peptides has been validated by the lack of bioactivity toward the cognate receptor in neighboring cells of the same in vitro culture. nAChRs in Xenopus oocyte cultures and voltage-gated calcium channels in 80% confluent HEK293 cultures are not inhibited by their cognate t-toxins, tethered ␣-bungarotoxin (t-␣Bgtx) and tethered -conotoxin MVIIA (t-MVIIA), expressed in co-cultured cells in the same dish (1, 21) . Similarly, co-cultures of HEK293 cells expressing PDFR and cells expressing t-PDF exhibit no receptor activation (6) . This cell autonomy is due to the tethering of the toxin or peptide to the cell surface by a covalent bond to a hydrophobic anchor embedded in the plasma membrane. Membrane tethering restricts the diffusion of the bioactive peptide to the plane of the plasma membrane, limiting its bioactivity to the cell that expresses the tethered ligand while preventing activity against neighboring cells that do not express the tethered ligand.
The first generation of t-toxins described in Ibanez-Tallon et al. (21) used the GPI targeting sequence from Lynx1 to recruit endogenously expressed GPI molecules as its molecular anchor. The same GPI targeting sequence was used in the design of the membrane-tethered forms of a variety of neurotoxins as well as Drosophila neuropeptides (1, 6, 19, 21, 34, 37) (FIGURE 1). In yeast, the GPI targeting sequence from the yeast GPI-anchored cell wall protein Yps1p was used for membrane-tethered ␣-factor, supporting the universality of the GPI-tethering method (14) (FIGURE 1).
A potential concern with using GPI as the membrane anchor is that the covalent bond between the GPI molecule and the peptide may be cleaved by GPI-specific phospholipases, such as phosphatidylinositol-specific phospholipase C (PI-PLC) or phospholipase D (31) . However, in mouse nociceptor primary cultures expressing t-MrVIA, immunoprecipitation assays detected that MrVIA enriched the membrane but not the culture media, indicating that such cleavage does not readily occur (34) . Furthermore, t-MrVIA activity was terminated upon treatment with PI-PLC, indicating that the tether is a requirement for the bioactivity of t-MrVIA (34). Similarly, an isoform of t-PDF that lacks the GPI targeting sequence fails to activate PDFR in cultured HEK293 cells and in vivo in Drosophila neurons (6) . One potential explanation for the loss of bioactivity caused by cleaving the tether is that the level of tethered ligand expression is insufficient to reach the bulk extracellular concentration required for bioactivity and that membrane-tethering increases the effective concentration of the ligand at the membrane surface by limiting its diffusion space. This also may explain how t-PDF achieves high bioactivity despite lacking the COOH-terminal amide modification critical for the high affinity of soluble PDF for its receptor (33) and suggests that the tether acts as a universal affinity domain. As (FIGURE 1) . These TM domains are type I TM domains with NH 2 terminal extracellular-COOH terminal intracellular orientation and, like GPI anchors, covalently link at the ligand COOH terminus and are effective with both exogenous neurotoxins and endogenous Class B1 peptide GPCR ligands (1, 6, 18, 19) . The TM anchor can be the superior choice over GPI if the GPI-tethered ligands have low bioactivity and expression levels, possibly due to misfolding or depletion of endogenous GPI available for tethered ligand synthesis. Although TM domains are bulkier than the lipid anchors of GPI molecules, potentially less mobile within the membrane surface and thus less potent, tethered ligands with TM anchors may express at a higher level (1) . However, because the expression level of TM anchors can vary as well depending on TM anchor sequence, type of the tethered ligand expressing cell, or identity of the ligand, whether to choose a TM anchor over a GPI anchor or which TM sequence to use should be determined on a case-by-case basis (1, 6) .
Nevertheless, some membrane-tethered ligand designs can only be made with TM anchors. With the GPI anchor design, useful functional modules, such as fluorescent tags, can be inserted within the linker domain or at the ligand NH 2 terminus. However, they might hamper the bioactivity of the ligand by steric hindrance of target binding or direct interaction with the ligand that disrupts the bioactive conformation. With TM anchors, those sequences can be added to the intracellular domain of the anchor, thus preventing ectopic interaction with the ligand (1, 18) (FIGURE 1). In addition, the tether orientation can be switched to link at the ligand NH 2 terminus by using type II TM domains that have a COOH-terminal extracellular orientation (FIGURE 1). This would allow the construction of bioactive tethered Class A GPCR ligands or other peptide ligands with critical COOH-terminal activity domains (17, 27) that are inactive when tethered at the COOH terminus (data not shown).
Linker Composition and Length
The linker domain connects the bioactive peptide ligand to the membrane anchor and confers required steric flexibility on the ligand to allow access to the specific binding site on its target. Thus the linker domain should consist of covalent bonds with high degrees of rotational freedom for the flexibility required to present the ligand to the receptor binding site in the appropriate orientation. Accordingly, successful tethered peptides, so far, have used either glycine-asparagine (GN) repeats or glycine-glycine-isoleucine (GGI) repeats, where the glycine-rich composition gives the covalent bonds of the linker the rotational freedom for flexibility (14, 21) . The length of the linker is also an important consideration, because it determines the diffusion space of the tethered ligand and its resulting effective local concentration and thus influences the efficacy of the bioactive ligand. The linker should be long enough for the tethered ligand to reach the binding site on the target molecule. However, a longer linker would increase the diffusion space of the ligand and decrease the effective concentration of the ligand at the binding site. This has been demonstrated experimentally by varying linker length, indicating that some tethered ligands require a minimum linker length for bioactivity (6, 14) . On the other hand, exceedingly long linkers have diminished bioactivity, and removal of the tether altogether renders the ligand inert, suggesting that the increase in effective concentration by limiting the diffusion space can be critical for bioactivity (6, 14, 18, 34) . Since the position of the specific binding site is unique to the ligand-receptor or toxin-target pair, the optimum linker length should be determined independently for each situation.
Application of T-Toxins in Model Organisms
The venoms of predators, such as scorpions, snakes, cone snails, and spiders, are cocktails of bioactive components that include a large number of genetically encoded peptides that evolved to perturb intercellular communication. In the last few decades, hundreds of peptide neurotoxins with specific bioactivities against various voltage-gated sodium, calcium, and potassium channel subtypes as well as various NMDA receptor and nAChR subtypes have been identified (reviewed in Refs. 4, 9) . The diversity and potency of these neurotoxins allows fast incapacitation of the nervous systems of a wide range of prey species. Also, this vast library of neurotoxins across various species is a tremendous natural resource for developing molecular tools for manipulating receptors and ion channels. In exploiting this amazing bioresource, the membrane-tethering approach is an effective means of delivering the specific bioactivity of neurotoxins in intact organisms. Transgenes encoding t-toxins based on any neurotoxins of known sequence and pharmacological specificity can be combined with cell-specific promoters to be delivered and expressed in vivo to modulate specific ion channels or receptors in a predictable way, thereby enabling the study of their roles in physiology and behavior. In addition, the membrane-tethered platform is well suited to screening of numerous uncharacterized peptide toxins against biologically and clinically important cloned targets in recombinant expression systems.
The usefulness of t-toxins in studying biological processes has been demonstrated in several model organisms. In zebrafish, delivery of a plasmid encoding tethered ␣-bungarotoxin (t-␣Bgtx), a snake venom-derived AChR inhibitor, under a muscle cell-specific promoter blocked ACh-induced currents in muscle cells expressing the t-toxin (21) . In chicken ciliary ganglion neurons, t-␣Bgtx expression by retrovirus vector injection into embryos also inhibited nAChR-mediated calcium signaling and the normal cell death during development mediated by nAChR signaling (19) (FIGURE 2) . In Drosophila melanogaster, approximately two dozen different UAS transgenes, each encoding a different GPI-tethered toxin derived from cone snail, spider, honey bee, and scorpion venom, have been generated for cell-specific expression of t-toxins using the GAL4-UAS binary expression system (37). Each t-toxin was expressed using a pan-neuronal elav-GAL4 driver for expression throughout the nervous system. Interestingly, of the t-toxins tested, it was only those derived from spider venoms with specificities for sodium channels, potassium channels, or calcium channels that caused lethality, consistent with the essential functional roles of these channels in the Drosophila nervous system (37) . Furthermore, the expression of such spider t-toxins in circadian pacemaker neurons resulted in viable animals with disrupted daily locomotor activity rhythms, indicating that the t-toxin-induced modulation of membrane biophysical properties is restricted to these specific neurons, thereby only influencing the particular biological process they control (37).
T-toxins were also effective in the dissection and modulation of the mouse pain transmission circuit. Pain transduction in mice is mediated by nociceptor neurons innervating the skin and muscle, whose excitability is controlled by TTX-resistant Na v 1.8 and TTX-sensitive Na v 1.7 voltage-gated sodium channels. Transgenic expression of the Na v 1.8-specific t-MrVIA under the nociceptor-specific Scn10a promoter resulted in a 40% reduction of Na v 1.8 currents in nociceptors but normal TTX-sensitive voltage-gated currents in t-MrVIA transgenics compared with wildtype controls (34) . This specific inhibition was accompanied by reduced firing rates in highthreshold, cold-sensitive c-fibers and ameliorated mechanical hyperalgesia after inflammation and nocifensive response to noxious cold, whereas lowthreshold c-fiber firing rates and behavioral responses to thermal and mechanical stimuli were unaffected, indicating the importance of Na v 1.8 channels in nociception and revealing the particular pain pathologies mediated by nociceptor Na v 1.8 channels (34) (FIGURE 2).
As an expansion on this study, nociceptor Ca v 2.2 channels that mediate presynaptic N-type calcium currents were targeted through transgenic expression of t-MVIIA in those cells to block synaptic output (1, 28) . The t-MVIIA transgenic mice exhibited impairment of a broader range of pain modalities, including neuropathic and inflammatory pain, consistent with inhibited synaptic transmission of pain signals from these neurons (1) . This led to the development of a general strategy for neuronal silencing in mice that is accomplished by the co-expression of t-MVIIA with a tethered -agatoxin AgaIVA (t-AgaIVA), which binds to Ca v 2.1 and blocks P-/Q-type calcium currents (16) . Co-expression of t-MVIIa and t-AgaIVA silenced
FIGURE 2. Examples of membrane-tethered ligands in model organisms
Schematics showing various membrane-tethered ligands with their target ion channels and receptors in specific chicken, mouse, and Drosophila cells in vivo and the physiological and behavior consequences of the manipulations. Venus and mCherry are fluorescent markers. inhibitory and excitatory postsynaptic currents in mouse hippocampal cultures (1) . In vivo unilateral injection of lentivirus carrying both t-toxins into the substantia nigra pars compacta (SNpc) caused unidirectional circling motor behavior, similar to the behavior caused by unilateral disruption of the nigrostriatal dopamine system, and indicated the disruption of dopaminergic neurotransmission from this brain region by t-toxin co-expression (1, 35) (FIGURE 2).
Studying Peptide-Receptor Signaling Circuits With T-Peptides
Neuropeptides and peptide hormones carry information from neurosecretory cells to cognate GPCRexpressing cells in multicellular circuits that control and modulate physiology and behavior, such as metabolism, appetite, and sleep. Tethered ligands encoding these neuropeptides and hormones can serve as cell-autonomous activators of their cognate GPCRs to upregulate signaling in vivo and produce informative cellular and organismal phenotypes. Also, by using cell-specific promoters, the upregulation can be localized to genetically determined groups of cells, and the different contributions of distinct subsets of cells within the circuit can be examined.
The usefulness of t-peptides in studying biological circuits in vivo was first demonstrated with the Drosophila neuropeptide PDF, whose daily secretion by circadian pacemaker neurons is a critical function of the circuit controlling normal sleep and daily locomotor activity rhythms (30, 32) . The pharmacologically specificity and cell autonomy of t-PDF demonstrated in HEK293 cells is also maintained in vivo in the context of the Drosophila circadian circuit. Expression of t-PDF in all Drosophila clock neurons using the clock neuron-specific tim-GAL4 driver constitutively activates PDFR and thus compromises the coherency of daily rhythms in constant conditions, manifested as multiple simultaneous rhythmic components free-running with different periods (complex rhythms) (6) . However, neither expression of t-DH31 in clock cells nor expression of t-PDF in glia resulted in any circadian phenotypes, supporting the pharmacological specificity and cell autonomy of t-PDF in vivo (6) . Because t-PDF expression in all glia did not induce any circadian phenotype, there is apparently no PDFR relevant for circadian control in glia and no transactivation of PDFRs in clock neurons by t-PDF expressed in neighboring glia (6) . These results indicate that t-PDF has the critical properties of pharmacologically specific bioactivity and cell autonomy, rendering it useful for dissecting neuropeptide signaling circuits.
In further experiments, t-PDF expression was restricted to subpopulations of PDFR-expressing neurons within the circadian circuit to drive PDFR activation in unique sets of clock neurons. t-PDF expression in the PDF-secreting pacemaker neurons themselves induced increased PDF and neurotransmitter secretion, increased locomotor activity at dawn, and accelerated locomotor rhythms in freerunning conditions (5) (FIGURE 2) . In contrast, t-PDF expression in clock neurons that do not secrete PDF led to acceleration of free-running locomotor rhythms or complex rhythms, depending on the specific subpopulation of clock neurons targeted (6) . These results reveal the presence of PDFR relevant to circadian control among different clock neurons, as well as their roles in accelerating or decelerating cellular oscillations and controlling cellular output to influence circadian locomotor behavior (5, 6). More generally, these studies highlight the effectiveness of using tethered neuropeptide ligands for deciphering endogenous peptide signaling in cellular circuits.
Future Potential
Membrane-tethered neurotoxins and endogenous signaling peptides have been developed as cellautonomous bioactive ligands with pharmacological specificity against particular ion channels, ionotropic receptors, and peptide GPCRs, and they have great potential for application in various aspects of biological study. As genetically encoded ligands, they can be deployed without the difficulties of obtaining high concentrations of soluble counterparts, and their sequences can be readily altered to better understand their molecular interaction with their targets (Refs. 10, 11; Gui J, Nitabach MN, unpublished observations). Also, membranetethered ligands are also effective in dissecting and manipulating biological circuits, and the approach can potentially be applied to any model organism with cell-specific transgenic expression systems.
This technique, however, is not without limitations. In designing membrane-tethered ligand transgenes, several different configurations may need to be tested before a potent membrane-tethered ligand is constructed. Also, their constitutive expression in vivo may induce compensatory changes in the circuit that might be difficult to distinguish from the direct effect of the membrane-tethered ligand. Light-or temperature-sensitive transgenic ion channels, such as channelrhodopsin-2 (ChR2), halorhodopsin (NpHR), or transient receptor potential cation channels (TrpA1), allow a high degree of temporal control but influence electrical properties of the cell to stimulate or inhibit neural output as a whole, which is less specific than the activation of endogenous intercellular signaling pathways by membrane-tethered ligands (3, 13, 39) .
Synthetic "caged-peptides" with inhibitory photolabile groups can be used to deliver peptide bioactivity via light with dynamics similar to light-sensitive ion channels and even greater spatial control than that afforded by transgenic expression systems, but they require tailored design and chemical synthesis for each peptide, and precise light delivery in behaving animals can be challenging (2) . On the other hand, transgenes such as membrane-tethered ligands can use drug-or temperature-inducible expression methods that can address adaptations that occur over days (1, 23, 36) . Furthermore, transgenic expression technology is rapidly progressing and promises to allow perturbation of cellular circuits by membrane-tethered ligands with greater precision than is currently available. Ⅲ Current address of C. Choi: Neurobiology Section, Division of Biological Sciences, University of California, 9500 Gilman Dr., San Diego, La Jolla, CA 92093.
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